Beginning in the late 1990s, Coventry noticed that some of his patients responded better to the Melanoma vaccine better than other patients despite receiving identical treatment. When local cancer tumours where injected with the vaccine, cancers that had not been injected began to shrink as well, thus indicating an immunogenic relationship. These observations led him to speculate that the immune system operates in a cyclical manner, with peaks and troughs. Operating on this theory, Coventry was able to increase complete response rates to treatment of advanced melanoma from 7% to 17% and without significant negative side effects. Publishing in the Journal of Translational Medicine in 2009, Coventry led a team which demonstrated that the immune cycle could be seen in fluctuating levels of C-reactive protein in the blood of a given patient. According to Coventry, "he immune system works in waves that seems to be switching on and off constantly. And now what we're trying to do is see whether we can identify periods or phases in that cycle where we could target the vaccine more effectively..." Crucially, the ability to administer treatment at the most effective time in a patient's immune cycle means that significantly smaller dosages of chemotherapy can be used, which in turn means far fewer negative side effects to treatment. Coventry, in his capacity as Research Director of the Australian Melanoma Research Foundation, has appeared before committees of the Parliament of Australia. In a 2014 submission to the Standing Committee on Health into Skin Cancer in Australia, it was stated that without the application of the new knowledge on the immune cycle cancer treatment was a "mathematically random" process. It was also revealed that treatment on mice with the new knowledge resulted in a "complete eradication of established tumours in 60% of mice". The 2015 submission to the Senate Standing Committee on Community Affairs Inquiry into the Availability of new, innovative and specialist cancer drugs in Australia states that the five-year survival rate of patients with advanced cancer is consistent with statistical probability that a patients treatment will be administered at exactly the right place in their immune cycle.
Other research
In a 20-year study published in the New EnglandJournal of Medicine, which Coventry co-authored, it was found that metastatic cancer can be located in the body through a process called "lymph node tracing". and Diane Ranck from Flinders University, 2009 Coventry was the lead author on a 2014 study which concluded that "isolated limb infusion is a minimally invasive alternative to isolated limb perfusion for delivering high-dose regional chemotherapy to treat locally advanced limb melanoma." A 2009 study in which Coventry participated discovered that melanoma rates were higher in areas that were coastal or bordered rivers, indicating that exposure was greater in these areas.
Activism
Speaking to the Scientific American in 2014, Coventry stated that “normous amounts of money and the brightest minds in biological and medical science have failed to make a big impact in the war on cancer, so maybe it’s time for a new paradigm”. He has also been critical of the undue influence of pharmaceutical companies over the Australian health care system, particularly because public tax revenues are used to pay for the inflated costs of treatment and the failure to improve survival rates. This has meant that billions of dollars have been spent, much of it on newer drugs, but without a corresponding improvement in treatment outcomes for patients with advanced cancer. In fact, the effectiveness of treatment for patients with advanced cancer has not had a notable improvement since the middle of the 20th century. Despite the discovery of the human immune cycle, the discovery of the ability to manipulate the cycle, and the ramifications of these discoveries for many immunologically related diseases, funding for the clinical trials has not been forthcoming from public grants schemes including the National Health and Medical Research Council.
